Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PerkinRA versus Kineret in children with systemic juvenile idiopathic arthritis
IRCT20190630044054N1Phase 3Completed
- Sponsor
- PersisGen
- Start
- May 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of anakinra in systemic juvenile idiopathic arthritis (SJIA) (2 arms), sponsored by PersisGen. Primary endpoint: ACR30 therapeutic response. Started May 2020; status: completed.
02
Drugs
anakinra
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on IRCT20190630044054N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190630044054N1.